TrialClinical pharmacology and therapeutics2019

M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.

Leona E Ling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.